Everything below concerns peptide research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-09. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
During examinations of the head and torso, this scattered radiation can spread throughout the body and is difficult to shield with radiation protective clothing. Fears that a lead apron will prevent radiation from leaving the body are unfounded, however, because lead absorbs radiation rather than scattering it. When preparing an orthopantomogram (OPG) for a dental overview radiograph, it is sometimes recommended not to wear a lead apron, as it does little to shield scattered radiation from the jaw area, but may hinder the rotation of the imaging device. However, according to the 2018 X-ray regulation, it is still mandatory to wear a lead apron when taking an OPG.
== Metal coordination == Being a type of molecules that are often only activated for biological and chemical function following metal-binding, the specific coordination of metal ions imposes certain restrictions and requirements onto metallopeptides. Usually metal cofactors are coordinated by nitrogen, oxygen or sulfur centers belonging to amino acid residues of the peptide. These donor groups can be introduced by histidine (or the corresponding imidazole), cysteine (thiolate group), as well as carboxylate substituents (e.g. by aspartate) but are not limited to these. The other amino acid residues, including non-natural amino acids and the peptide backbone have been shown to bind metal centers and provide donor groups. The research on metal-binding of peptides ranges from coordination of biometals (such as Calcium, Magnesium, Manganese, Zinc, Sodium, Potassium, and Iron) to heavy metals (such as Arsenic, Mercury, and Cadmium).
==== Borderline personality disorder ==== Similar epigenetic alterations in OPRK1 methylation patterns have been linked to borderline personality disorder (BPD), where an imbalance between opioid receptor systems could cause symptoms such as chronic dysphoria, suicidality, and emotional instability. In individuals with BPD, decreased DNA methylation (hypomethylation) in a differentially methylated region (DMR) located within the promoter region, specifically at a cluster of five adjacent CpG sites (CG34–CG38) positioned immediately upstream of core CpG islands (CGI-1 and CGI-2), results in enhanced gene transcription and elevated KOR expression. The DMR hypomethylation in BPD is strategically positioned on the "falling slope" of the gene's methylation gap; a transition zone between the sparsely methylated CpG island promoter and densely methylated downstream regions. This location amplifies the functional consequences of hypomethylation by progressively steepening the methylation gradient, further facilitating transcription initiation at multiple transcription start sites (TSS) distributed throughout the CGI promoter region. Consequently, the decreased methylation rates in the DMR are associated with increased OPRK1 mRNA transcription and heightened KOR protein expression in peripheral white blood cells and, by extension, in central brain regions involved in emotion regulation. Symptom severity in BPD correlates with DMR hypomethylation levels.
Sources: en.wikipedia.org
=== Asbestos === While Grace no longer makes asbestos or related products, at the time of its bankruptcy in 2001, it faced over 65,000 asbestos-related personal injury lawsuits involving over 129,000 claims. On April 2, 2001, Grace and its subsidiaries in the United States filed voluntary petitions for Chapter 11 Bankruptcy reorganization in the Bankruptcy Court for the District of Delaware. The company was trying to find a resolution through federal court-supervised reorganization in response to the quickly growing number of asbestos-related bodily injury claims. On September 19, 2008, Grace filed a revised plan of reorganization to the same court, jointly with the asbestos injury claimants. In January 2011, the court issued an order in favor of the new plan and in January 2012, the court denied all appeals and affirmed the plan. After a motion for reconsideration, the plan was reaffirmed on June 11, 2012. On February 3, 2014, Grace emerged from the asbestos-related Chapter 11 bankruptcy, which took more than 12 years. Under the plan of reorganization approved by the court, all parties filings the asbestos-related claims were to direct their inquiry to either an asbestos personal injury trust or a separate asbestos property damage trust.
The Spanish American wars of independence (Spanish: Guerras de independencia hispanoamericanas) were a series of conflicts across the Spanish Empire in the early 19th century. They began shortly after the outbreak of the Peninsular War and formed part of the broader Napoleonic Wars. The process unfolded in two main phases. First, the Spanish Monarchy broke up, beginning in Spain in 1808 with the invasion by the French Empire, the Spanish uprising against the Bonapartes, the vacancy of the throne, and the emergence of juntas later replicated in America. This unfolded as it did because the monarchy's basic cellular structure was the cabildo (town council, or ayuntamiento). Second, attempts at reconstruction failed and became a war in their own right: Cádiz sought a pan-Hispanic state, Ferdinand VII sought to restore the Crown returned to him by Napoleon, and in the Americas Bolívar, Iturbide and others tried to build large federations or empires. The result was the fragmentation of the Hispanic world into multiple states that largely reconstituted the old Spanish administrative boundaries under uti possidetis. The conflicts were multilateral, involving factions grouped into two camps: Royalists, who favoured continued Spanish rule, and Patriots, who supported independent monarchies or republics separate from Spain and from one another. They led to the independence of most of Spanish America and, through Balkanization, to Hispanic America. Defined strictly by military campaigns, they ran from the 1809 Battle of Chacaltaya (Bolivia) to the 1829 Battle of Tampico (Mexico).
On Colombia's Caribbean coast, tajadas of fried green plantain are consumed along with grilled meats, and are the dietary equivalent of the French-fried potatoes/chips of Europe and North America. After removing the skin, maduro can be sliced (between 3 and 20 mm or 1⁄8–25⁄32 in thick) and pan-fried in oil until golden brown or according to preference. In the Dominican Republic, Ecuador, Colombia, Honduras (where they are usually eaten with the native sour cream) and Venezuela, they are also eaten baked in the oven (sometimes with cinnamon). In Puerto Rico baked plátanos maduros are usually eaten for breakfast and served with eggs (mainly an omelet with cheese), chorizo or bacon. Only salt is added to green plantains. Tacacho is a roasted plantain Amazonian cuisine dish from Peru. It is usually served con cecina, with bits of pork. In Venezuela, a yo-yo is a traditional dish made of two short slices of fried ripened plantain (see Tajada) placed on top of each other, with local soft white cheese in the middle (in a sandwich-like fashion) and held together with toothpicks. The arrangement is dipped in beaten eggs and fried again until the cheese melts and the yo-yo acquires a deep golden hue. They are served as sides or entrees. In Puerto Rico fried plantains are served in a variety of ways as side dishes, fast foods, and main course. An alternative to tostones are arañitas (little spiders). The name comes from the grated green and yellow plantain pieces forming little legs that stick out of the fritter itself, which ends up looking like a prickly spider on a plate.
=== Cliff swallows === Populations of cliff swallows in Nebraska have displayed morphological changes in their wings after many years of living next to roads. Collecting data for over 30 years, researchers noticed a decline in wingspan of living swallow populations, while also noting a decrease in the number of cliff swallows killed by passing cars. Those cliff swallows that were killed by passing cars showed a larger wingspan than the population as a whole. Confounding effects such as road usage, car size, and population size were shown to have no impact on the study.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.